Crinetics | News & Events

PRESS RELEASES

Press Release | June 14, 2026

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Press Release | June 14, 2026

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Press Release | June 2, 2026

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

Press Release | June 2, 2026

Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

Press Release | May 22, 2026

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

Press Release | May 7, 2026

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Press Release | April 27, 2026

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Press Release | April 8, 2026

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Press Release | March 26, 2026

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Press Release | February 26, 2026

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

1 / 25

Transforming Endocrine Disease Treatment

Be the first to know about the advances we're making in endocrine-rooted care.

Email Signup